PLX038 for brain tumors with MYC or MYCN changes
Part of Brain & nervous system, Cancer clinical trials.
This study tests a new drug called PLX038 for people with brain or spinal cord tumors that have certain genetic changes (MYC or MYCN) or have come back after treatment. The drug is given as an infusion and targets tumor cells. The study aims to see if the drug is safe and effective for different types of these tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a primary brain or spinal cord tumor that has come back or is growing.
- For some parts of the study, the tumor must have a specific genetic change (MYC or MYCN amplification).
- You are 18 years or older.
- You are generally able to care for yourself (Karnofsky score 70% or higher).
- You have had a break from prior treatments like chemotherapy or radiation (at least 4 weeks, sometimes longer).
- You have tumor tissue available for testing, or you are willing to have a biopsy if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug, TLX101-Tx, added to standard care for people with glioblastoma that has come back after initial treatment. It aims to see if the combination helps control the tumor better than standard care alone.
This trial looks at a new way to treat a type of brain tumor called Group 3 medulloblastoma. Researchers want to understand how targeting a protein called MYC might help, and they will study tumor tissue from surgery.
This trial tests a combination of two experimental drugs, CTX-009 and CTX-471, for people whose glioblastoma has returned. The goal is to see if these drugs can help control the tumor.
This study tests FT536, a new cell-based treatment, for people with a specific type of brain cancer (WHO Grade 4 astrocytoma) that has come back after standard treatment. The trial combines the new therapy with surgery to see if it can help stop the cancer from growing further.
This study tests a new way to choose treatment for people with brain tumors that have not responded to standard therapies. Your tumor sample is analyzed in the lab to find which drugs might work best for you, and then you receive a personalized treatment plan.
This trial tests a new drug, CBX-663, for people with certain blood cancers, advanced solid tumors, or a type of brain cancer called glioblastoma that has returned or not responded to standard treatment. The goal is to see if the drug is safe and if it helps shrink tumors or control the cancer.
Hear when a new Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.